SCHEMBL2642286

SCHEMBL2642286

N#Cc1cncc(N)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29919144 1.00
SCHEMBL5802182 0.88 HTT (0.46)
Formic Acid Methyl Ester SCHEMBL28548127 0.82 RAF1 (0.36)
SCHEMBL936524 0.82 CYP11B1 (0.47)
SCHEMBL1476753 0.80 GRM5 (0.47)
Hydrochloric Acid SCHEMBL28737416 0.79 CYP11B1 (0.46)
SCHEMBL28184881 0.79 CYP11B1 (0.46)
Tert-Butyl Formate SCHEMBL27945534 0.79 TDP1 (0.38)
SCHEMBL503854 0.76
SCHEMBL1476791 0.76 GRM5 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117832605-B Composite solid electrolyte and all-solid-state lithium battery cell 东莞市红树林新能源有限公司 2024-06-11 CN claimed
CN-117832605-A Composite solid electrolyte and all-solid-state lithium battery cell 东莞市红树林新能源有限公司 2024-04-05 CN claimed
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-05-07 US disclosed
EP-4720046-A1 SULFONAMIDE COMPOUNDS AS CAV2.3 ANTAGONISTS Lario Therapeutics Limited (GB) 2026-04-08 EP disclosed
US-20260090270-A1 ORGANIC ELECTRONIC ELEMENT AND COMPOUND TOSOH CORPORATION (JP) 2026-03-26 US disclosed
EP-4709712-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF Blueprint Medicines Corporation (US) 2026-03-18 EP disclosed
EP-4334298-B1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS INC (US) 2026-02-18 EP disclosed
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2026-01-20 US disclosed
EP-4678634-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF Haihe Biopharma Co., Ltd. (CN) 2026-01-14 EP disclosed
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
EP-4638445-A1 1,2,4-THIAZOLIDIN-3-ONE-1,1-DIOXIDE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE Bristol-Myers Squibb Company (US) 2025-10-29 EP disclosed
WO-2007045861-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2007-04-26 WO disclosed
WO-2007042299-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007034312-A2 PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) PFIZER PRODUCTS INC. (US) 2007-03-29 WO disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed
CN-1043760-C \"Pyridinecarboximidamide compounds and the use thereof\ KIRN BEER KABUSHIKI KAISHA (JP) 1999-06-23 CN disclosed
EP-0634400-B1 PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF KIRIN BREWERY (JP) 1997-04-02 EP disclosed
US-5508293-A TREATING HYPERTENSION, ANGINA PECTORIS KIRIN BEER KABUSHIKI KAISHA (JP) 1996-04-16 US disclosed
EP-0634400-A1 PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF KIRIN BEER KABUSHIKI KAISHA (JP) 1995-01-18 EP disclosed
CN-1077949-A Pyridine carboxy imido acid amide compound and application thereof KIRIN BREWERY (JP) 1993-11-03 CN disclosed